Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.62 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.62 |
| ▸ | SGPL1 | O95470 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159967 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL4159965 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL4176098 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL2292830 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL10299886 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL10078592 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL4173831 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL10078494 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL10078493 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 | |
| SCHEMBL10299885 | 1.00 | S1PR3 (0.76) | S1PR3S1PR1S1PR4S1PR5SGPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | S1PR3 2/4885S1PR1 1/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.